Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

Breast Cancer

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

Ann Oncol

Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)

doi: 10.1016/j.annonc.2026.05.703

Gastrointestinal Cancer

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

J Clin Oncol

Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Pietrantonio F, Lonardi S, Fang X, Guan Y, Valderrama A, Leconte P, Bhagia P, Bang YJ, KEYNOTE-585 Investigators

doi: 10.1200/JCO-25-00486

Breast Cancer

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial

Int J Cancer

Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, Brucker SY, Köhler U, Heinrich G, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Rack B, Heublein S, Ziegler P

doi: 10.1002/ijc.70528

Gastrointestinal Cancer

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Cancer Cell

Bai X, Li X, Chen Y, Qiao G, Zhang Q, Ma T, Gao S, Zhang M, Shen Y, Wu J, Yu J, Que R, Zhang X, Sun K, Xiao W, Jiang T, Liang T

doi: 10.1016/j.ccell.2025.09.009

Lung, Respiratory and Thoracic Cancer

Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial

Ann Oncol

Wang C, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Zhang Z, Yao B, Wang S, Leaw S, Naicker K, Zheng W, Yu C, Yue D, RATIONALE-315 investigators

doi: 10.1016/j.annonc.2025.11.017

Genitourinary Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

Eur Urol

Kitamura H, Tsukamoto T, Kakehi Y, Mizusawa J, Shibata T, Sasaki K, Tanikawa T, Hashine K, Fujimoto K, Masumori N, Kobayashi T, Habuchi T, Kimura T, Sugimoto M, Takahashi A, Adachi H, Matsui Y, Hatakeyama S, Ito A, Eto M, Nishiyama H, Urologic Oncology Study Group of the Japan Clinical Oncology Group

doi: 10.1016/j.eururo.2026.01.008

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

SPECIAL REPORT

Gynecologic Cancer

Related content

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer